Veterinary Antihistamines Market Size to Hit USD 2.12 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Veterinary Antihistamines Market

5.1. COVID-19 Landscape: Veterinary Antihistamines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Veterinary Antihistamines Market, By Drug Type

8.1. Veterinary Antihistamines Market Revenue and Volume Forecast, by Drug Type

8.1.1. H1 Receptor Antagonists (H1 Blockers)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. H2 Receptor Antagonists (H2 Blockers)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Others (Dual-acting, mast-cell stabilizers, etc.)

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Veterinary Antihistamines Market, By Dosage Form

9.1. Veterinary Antihistamines Market Revenue and Volume Forecast, by Dosage Form

9.1.1. Tablets & Capsules

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Injectables

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Oral Liquids & Suspensions

9.1.3.1. Market Revenue and Volume Forecast

9.1.3. Oral Liquids & Suspensions

9.1.3.1. Market Revenue and Volume Forecast

9.1.3. Topical Creams & Gels

9.1.3.1. Market Revenue and Volume Forecast

9.1.3. Others (powders, chewables, sprays)

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Veterinary Antihistamines Market, By Animal Type

10.1. Veterinary Antihistamines Market Revenue and Volume Forecast, by Animal Type

10.1.1. Dogs

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Cats

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Equine

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Cattle

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Swine

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Others (goats, rabbits, exotic pets)

10.1.6.1. Market Revenue and Volume Forecast

Chapter 11. Global Veterinary Antihistamines Market, By Distribution Channel

11.1. Veterinary Antihistamines Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Veterinary Clinics/Hospitals

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Others (distributors, pet shops)

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Veterinary Antihistamines Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug Type

12.1.2. Market Revenue and Volume Forecast, by Dosage Form

12.1.3. Market Revenue and Volume Forecast, by Animal Type

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug Type

12.1.5.2. Market Revenue and Volume Forecast, by Dosage Form

12.1.5.3. Market Revenue and Volume Forecast, by Animal Type

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug Type

12.1.6.2. Market Revenue and Volume Forecast, by Dosage Form

12.1.6.3. Market Revenue and Volume Forecast, by Animal Type

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug Type

12.2.2. Market Revenue and Volume Forecast, by Dosage Form

12.2.3. Market Revenue and Volume Forecast, by Animal Type

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug Type

12.2.5.2. Market Revenue and Volume Forecast, by Dosage Form

12.2.5.3. Market Revenue and Volume Forecast, by Animal Type

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug Type

12.2.6.2. Market Revenue and Volume Forecast, by Dosage Form

12.2.6.3. Market Revenue and Volume Forecast, by Animal Type

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug Type

12.2.7.2. Market Revenue and Volume Forecast, by Dosage Form

12.2.7.3. Market Revenue and Volume Forecast, by Animal Type

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug Type

12.2.8.2. Market Revenue and Volume Forecast, by Dosage Form

12.2.8.3. Market Revenue and Volume Forecast, by Animal Type

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug Type

12.3.2. Market Revenue and Volume Forecast, by Dosage Form

12.3.3. Market Revenue and Volume Forecast, by Animal Type

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug Type

12.3.5.2. Market Revenue and Volume Forecast, by Dosage Form

12.3.5.3. Market Revenue and Volume Forecast, by Animal Type

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug Type

12.3.6.2. Market Revenue and Volume Forecast, by Dosage Form

12.3.6.3. Market Revenue and Volume Forecast, by Animal Type

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug Type

12.3.7.2. Market Revenue and Volume Forecast, by Dosage Form

12.3.7.3. Market Revenue and Volume Forecast, by Animal Type

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug Type

12.3.8.2. Market Revenue and Volume Forecast, by Dosage Form

12.3.8.3. Market Revenue and Volume Forecast, by Animal Type

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug Type

12.4.2. Market Revenue and Volume Forecast, by Dosage Form

12.4.3. Market Revenue and Volume Forecast, by Animal Type

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug Type

12.4.5.2. Market Revenue and Volume Forecast, by Dosage Form

12.4.5.3. Market Revenue and Volume Forecast, by Animal Type

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug Type

12.4.6.2. Market Revenue and Volume Forecast, by Dosage Form

12.4.6.3. Market Revenue and Volume Forecast, by Animal Type

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug Type

12.4.7.2. Market Revenue and Volume Forecast, by Dosage Form

12.4.7.3. Market Revenue and Volume Forecast, by Animal Type

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug Type

12.4.8.2. Market Revenue and Volume Forecast, by Dosage Form

12.4.8.3. Market Revenue and Volume Forecast, by Animal Type

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug Type

12.5.2. Market Revenue and Volume Forecast, by Dosage Form

12.5.3. Market Revenue and Volume Forecast, by Animal Type

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug Type

12.5.5.2. Market Revenue and Volume Forecast, by Dosage Form

12.5.5.3. Market Revenue and Volume Forecast, by Animal Type

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug Type

12.5.6.2. Market Revenue and Volume Forecast, by Dosage Form

12.5.6.3. Market Revenue and Volume Forecast, by Animal Type

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Virbac

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerDrug Typeance

13.1.4. Recent Initiatives

13.2. Dechra Pharmaceuticals

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerDrug Typeance

13.2.4. Recent Initiatives

13.3. Bimeda

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerDrug Typeance

13.3.4. Recent Initiatives

13.4. Neogen Corporation

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerDrug Typeance

13.4.4. Recent Initiatives

13.5. Phibro Animal Health

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerDrug Typeance

13.5.4. Recent Initiatives

13.6. Vétoquinol

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerDrug Typeance

13.6.4. Recent Initiatives

13.7. Ourofino Saúde Animal

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerDrug Typeance

13.7.4. Recent Initiatives

13.8. Kyoritsu Seiyaku Corporation

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerDrug Typeance

13.8.4. Recent Initiatives

13.9. Chanelle Pharma

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerDrug Typeance

13.9.4. Recent Initiatives

13.10. KRKA Pharmaceuticals

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerDrug Typeance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The veterinary antihistamines market size is expected to increase from USD 1.25 billion in 2024 to USD 2.12 billion by 2034.

The veterinary antihistamines market is expected to grow at a compound annual growth rate (CAGR) of around 5.43% from 2025 to 2034.

The major players in the veterinary antihistamines market include Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health, Merck Animal Health, Virbac, Dechra Pharmaceuticals, Vetoquinol, Ceva Santé Animale, Bayer Animal Health (now part of Elanco), Norbrook Laboratories, Bimeda, Neogen Corporation, Phibro Animal Health, Vétoquinol, Ourofino Saúde Animal, Kyoritsu Seiyaku Corporation, Med-Pharmex, KRKA Pharmaceuticals, Chanelle Pharma, and PetIQ Inc.

The driving factors of the veterinary antihistamines market are the increase of allergic reactions to environmental allergens is propelling the veterinary antihistamines market forward.

North America region will lead the global veterinary antihistamines market during the forecast period 2025 to 2034.